Rigetti Faces Revenue Volatility and Rising Costs Despite Quantum Push

Rigetti's Q2 2026 revenue rose to $5.1M from $1.8M, but 80% of sales came from two customers and recognition of an $8.4M India C-DAC contract is deferred until Q4 installation and acceptance. Operating expenses increased 48% to $30.3M, including a 53% rise in R&D to $20.7M, producing a $28.1M operating loss; elevated capex, sustained losses and dilution risk remain key concerns despite $541.3M of liquidity. RGTI shares are down 31.1% year to date, trade at 9.48x price-to-book, and carry a Zacks Rank #5 (Strong Sell).

Analysis

RGTI's issue is not simply weak profitability; it is that its revenue model remains dominated by episodic hardware acceptance rather than a compounding installed-base or software/service stream. That makes quarterly results unusually vulnerable to customer procurement timing and acceptance delays, while fixed R&D and fab costs continue to scale ahead of utilization. The cash balance reduces near-term solvency risk, but it also permits a longer period of negative operating leverage and raises the probability that equity value is diluted before commercial economics are proven.

Relative positioning favors IONQ over RGTI for the next 1-3 months: enterprise security integration creates a clearer route to budgeted IT spending, whereas RGTI is still principally exposed to research-system purchases. SKYT is a second-order beneficiary if ion-trap fabrication milestones translate into recurring foundry demand, although the economic value to SkyWater depends on production volumes rather than prototype announcements. QBTS has a potentially meaningful non-dilutive funding advantage, but its weaker margin execution means the market may discount the award until bookings convert into revenue and gross-margin recovery.

The near-term contrarian case for RGTI is a Q4 revenue-recognition squeeze if installation is completed on schedule; given a small base, a single accepted system can produce an optically large beat. That is a trading catalyst, not evidence of durable commercialization. The structural downside reasserts over 6-18 months unless RGTI demonstrates repeat purchases, materially broader customer concentration, and operating-expense growth below revenue growth; any additional equity issuance or delayed acceptance would invalidate a tactical long case immediately.

Key Decisions for Investors

• Maintain an IONQ / RGTI relative-value long/short through the next 1-3 months, sized beta-neutral. The spread expresses differentiated commercialization quality rather than broad quantum sentiment; cover if RGTI reports repeat enterprise orders or IONQ's enterprise-security agreement fails to convert into disclosed backlog or guidance support.
• Do not establish a directional RGTI long ahead of Q4 solely on the expected project acceptance. Put RGTI on a catalyst watch: consider a short-duration post-confirmation trade only if recognized revenue is accompanied by new order backlog, reduced customer concentration, and no material upward revision to cash-burn guidance.
• For exposure to domestic quantum supply-chain optionality, prefer a small SKYT watch position over direct RGTI exposure, contingent on disclosure that prototype work advances to production wafer volume. Falsifier: absent volume commitments or foundry-segment revenue contribution over the next two earnings reports, the linkage remains promotional rather than investable.
• Avoid chasing QBTS on government-funding headlines; reassess after the next earnings release for bookings growth and gross-margin stabilization. A long QBTS becomes more defensible only if non-dilutive funds displace planned equity financing and commercial revenue converts at improving margins.